---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-051603"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:24:10.566840+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lyell reports Q3 net loss $38.8M, cash $320M; acquires LYL273 CAR T for mCRC with 67% ORR

## Summary
- Net loss $38.8M vs $44.6M YoY; non-GAAP net loss $29.1M.
- Cash $320M, expected to fund pipeline into 2027.
- Acquired exclusive global rights to LYL273 (GCC-targeted CAR T) from ICT; Phase 1 data: 67% ORR at highest dose in refractory mCRC.
- FDA granted RMAT designation for ronde-cel in 2L LBCL; PiNACLE-H2H Phase 3 trial expected to start by early 2026.
- Two ronde-cel abstracts accepted for oral presentation at ASH 2025.

## SEC filing metadata
- accession: 0001628280-25-051603
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828025051603/0001628280-25-051603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828025051603/lyel-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-051603
- JSON: https://secwatch.observer/filing/0001628280-25-051603.json
- Plain text: https://secwatch.observer/filing/0001628280-25-051603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.